Trans-Arterial Micro-perfusion (TAMP™) is an Innovative Therapy Platform Designed for Localized and Targeted Delivery of Existing and Novel Oncology Agents to Tumors
Our proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. TAMP is enabled by our patented, FDA-cleared RenovoCath® device. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. RenovoRx’s novel approach to targeted treatment offers patients with solid tumor cancers the potential for increased safety, tolerance, and improved efficacy.
In addition to the RenovoCath device, we are also evaluating our novel combination oncology product candidate, IAG, which utilizes RenovoCath. The combination oncology product candidate is currently being evaluated for the treatment of LAPC under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. The combination product candidate, enabled the RenovoCath device, is currently under investigation and has not been approved for commercial sale.
Learn more about TAMP by watching this animation:
Localized and Targeted Therapy
TAMP is specifically designed for the localized and targeted delivery of chemotherapy via the peripheral vascular system. TAMP begins with standard artery access, where the RenovoCath device is inserted through the blood vessels to target the tumor. RenovoCath’s double balloon design enables the physician to isolate sections of the blood vessel through the adjustment of the distance between the balloons, thereby excluding any side branches in order to create the pressure head needed to push chemotherapy across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy.
Standard of care for patients diagnosed with most forms of cancer is intravenous systemic chemotherapy, which typically has significant side effects and can be limited in its effectiveness based on cancer type. For example, liver cancer tumors are highly vascularized and typically have large tumor feeders or blood vessels connected to the tumor, making them better candidates for systemic chemotherapy because medicine is able to gain direct access to the tumor. In contrast, several solid tumors lack visible tumor feeder blood vessels, which means the chemotherapy can circulate through the body, without a significant amount of medicine reaching the tumor.
Targeted Delivery In Action
The first of two interim analyses was completed in March 2023, and the DMC recommended a continuation of the study. The study is prespecified to provide a primary endpoint of a 6-month OS benefit and secondary endpoints including reduced side effects versus standard of care.
Caution: Federal (USA) law restricts the RenovoCath device to sale by or on the order of a physician.
The RenovoRx device (“RenovoCath”) is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. Our device is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. Prior to use, please refer to the RenovoRx IFU for complete product indications, warnings, precautions, contraindications, potential adverse effects and detailed instructions for use.